Turkey Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Turkey Pharmaceuticals and Healthcare Report

Turkey Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Turkey Pharmaceuticals and Healthcare Report
Published Jun 25, 2016
88 pages — Published Jun 25, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In BMI s Q--- Pharmaceutical Risk/Reward Index (RRI) Turkey is ranked --th out of the -- markets in the Central and Eastern European (CEE) matrix with a downgraded score of --.- compared with the previous quarter (--.-). Turkey scores above the regional average score of --.- in Q---. ...Turkey scores above the regional average score of --.- in Q---. The country s overall Rewards score of ---.- is considerably higher than the regional average (--.-) despite a lower-than- average County Rewards score, due to its large total market size and long-term growth potential. Its overall score is limited by below regional-average scores for both Industry and Country Risks, due to its continued poor regulatory environment. ...The country s overall Rewards score of ---.- is considerably higher than the regional average (--.-) despite a lower-than- average County Rewards score, due to its large total market size and long-term growth potential. Its overall score is limited by below regional-average scores for both Industry and Country Risks, due to its continued poor regulatory environment.

...Government opposition to aligning domestic patent law fully with international norms. Government fiscal conservatism continues to damage finances of domestic pharmaceutical industry through tightening pricing and reimbursement policies. ...Government opposition to aligning domestic patent law fully with international norms. Government fiscal conservatism continues to damage finances of domestic pharmaceutical industry through tightening pricing and reimbursement policies. The costs of modernisation could deter the harmonisation of the domestic regulatory infrastructure and industry standards with international norms. The potential concentration of the supplier base as a result of increasing mergers and acquisitions. Political tensions with Russia following the downing of a Russian jet risk having an impact on trade between the two countries.

...Relatively low per-capita drug spending compared with other European markets. Fiscal conservatism in public pharmaceutical expenditure due to government attempts to control spending. ...

  
Source:
Document ID
1748-2259
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
   643
  Sanovel Pharmaceuticals672
  Deva (EastPharma)693
  Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals724
  Pfizer762
  Sanofi782
  GlaxoSmithKline802
  Roche822
  AstraZeneca841
  Bayer852
  Merck &Co871
CONTENTS33
Executive Summary62
SWOT Analysis83
Pharmaceuticals &Healthcare Risk/Reward Ratings113
  Rewards121
  Risks122
Turkey Market Summary141
Regulatory Regime158
  Intellectual Property Regime161
  Market Access Issues171
  Pricing Regime182
  Drug Price Inflation201
  Reimbursement Regime212
Industry Developments239
  Epidemiology231
  Non-Communicable Diseases231
  Healthcare Sector241
  Healthcare Insurance251
  Healthcare Infrastructure261
  Healthcare Financing271
  Research &Development271
  Clinical Trials Industry281
  Medical Devices Industry293
Industry Forecast Scenario3223
  Overall Market Forecast323
  Healthcare Market Forecast353
  Key Growth Factors Macroeconomic385
  Prescription Drug Market Forecast432
  Patented Drug Market Forecast451
  Generic Drug Market Forecast462
  OTC Medicine Market Forecast482
  Pharmaceutical Trade Forecast502
  Medical Device Market Forecast522
  Other Healthcare Data541
  Key Risks To BMI s Forecasts541
Competitive Landscape556
  Pharmaceutical Sector551
  Domestic Industry561
  Foreign Industry561
  Company Activity571
  Wholesale581
  Retail592
Company Profiles6128
  Local Companies6114
  Multinational Companies7514
Demographic Outlook894
Glossary932
BMI Methodology954
  How We Generate Our Pharmaceutical Industry Forecasts951
  Risk/Reward Ratings Methodology961
  Ratings Overview962
  Weighting981

Table Of Contents

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Turkey Pharmaceuticals and Healthcare Report" Jun 25, 2016. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Turkey-Pharmaceuticals-and-Healthcare-Report-2026-304>
  
APA:
Business Monitor International - Industry Reports. (2016). Turkey Pharmaceuticals and Healthcare Report Jun 25, 2016. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Turkey-Pharmaceuticals-and-Healthcare-Report-2026-304>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.